Vaccination with a booster dose of COVID-19 mRNA vaccine has been associated with decreased risk of developing severe COVID-19 compared with no vaccination.1,2 However, among individuals already fully vaccinated with the primary series of an mRNA vaccine, less is known about how much protection is added by a booster and how long that protection lasts. We assessed the association between COVID-19 mRNA booster immunization compared with vaccination with the primary mRNA vaccination series alone and the odds of hospitalization for COVID-19.
Sign in to take quiz and track your certificates
JN Learning™ is the home for CME and MOC from the JAMA Network. Search by specialty or US state and earn AMA PRA Category 1 Credit(s)™ from articles, audio, Clinical Challenges and more. Learn more about CME/MOC
CME Disclosure Statement: Unless noted, all individuals in control of content reported no relevant financial relationships. If applicable, all relevant financial relationships have been mitigated.
Accepted for Publication: September 12, 2022.
Published Online: September 23, 2022. doi:10.1001/jama.2022.17811
Corresponding Author: Jessica P. Ridgway, MD, Department of Medicine, University of Chicago, 5841 S Maryland Ave, MC 5065, Chicago, IL 60637 (Jessica.firstname.lastname@example.org).
Author Contributions: Dr Robicsek had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Concept and design: Ridgway, Tideman, Wright, Diaz, Robicsek.
Acquisition, analysis, or interpretation of data: All authors.
Drafting of the manuscript: Ridgway, Tideman, Wright, Robicsek.
Critical revision of the manuscript for important intellectual content: Tideman, French, Wright, Parsons, Diaz, Robicsek.
Statistical analysis: Tideman, French, Wright, Robicsek.
Obtained funding: Robicsek.
Administrative, technical, or material support: Tideman, Parsons, Diaz, Robicsek.
Supervision: Parsons, Robicsek.
Conflict of Interest Disclosures: Dr Ridgway reported receiving personal fees from Gilead Sciences. Dr Diaz reported receiving grants from Gilead, Roche, Regeneron, Edesa Biotech Inc, Boehringer Ingelheim, NeuroBo Pharmaceuticals Inc, and the National Institutes of Health and serving as a scientific board member for Safeology. No other disclosures were reported.
Credit Designation Statement: The American Medical Association designates this Journal-based CME activity activity for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to:
It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting MOC credit.
You currently have no searches saved.
You currently have no courses saved.